<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title></journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2014.2103</article-id>
<article-id pub-id-type="publisher-id">ol-08-01-0007</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Histological and molecular aspects of oral squamous cell carcinoma (Review)</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>RIVERA</surname><given-names>C&#x000C9;SAR</given-names></name><xref rid="af1-ol-08-01-0007" ref-type="aff">1</xref><xref rid="af2-ol-08-01-0007" ref-type="aff">2</xref><xref ref-type="corresp" rid="c1-ol-08-01-0007"/></contrib>
<contrib contrib-type="author">
<name><surname>VENEGAS</surname><given-names>BERNARDO</given-names></name><xref rid="af3-ol-08-01-0007" ref-type="aff">3</xref></contrib></contrib-group>
<aff id="af1-ol-08-01-0007">
<label>1</label>Unit of Histology and Embryology, Department of Basic Biomedical Sciences, Faculty of Health Sciences, University of Talca, Talca 3460000, Chile</aff>
<aff id="af2-ol-08-01-0007">
<label>2</label>Biomedical Sciences Master Program, Oral Pathology Mention, Faculty of Health Sciences, University of Talca, Talca 3460000, Chile</aff>
<aff id="af3-ol-08-01-0007">
<label>3</label>Unit of Oral Pathology, Department of Dentistry, Faculty of Health Sciences, University of Talca, Talca 3460000, Chile</aff>
<author-notes>
<corresp id="c1-ol-08-01-0007">Correspondence to: Dr C&#x000E9;sar Rivera, Department of Basic Biomedical Sciences, Faculty of Health Sciences, University of Talca, Avenida Lircay S/N, Maule Region, Talca 3460000, Chile, E-mail: <email>contacto@cesarrivera.cl</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>7</month>
<year>2014</year></pub-date>
<pub-date pub-type="epub">
<day>29</day>
<month>04</month>
<year>2014</year></pub-date>
<volume>8</volume>
<issue>1</issue>
<fpage>7</fpage>
<lpage>11</lpage>
<history>
<date date-type="received">
<day>23</day>
<month>07</month>
<year>2013</year></date>
<date date-type="accepted">
<day>13</day>
<month>02</month>
<year>2014</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2014, Spandidos Publications</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>Oral squamous cell carcinoma (OSCC) represents 95&#x00025; of all forms of head and neck cancer, and over the last decade its incidence has increased by 50&#x00025;. Oral carcinogenesis is a multistage process, which simultaneously involves precancerous lesions, invasion and metastasis. Degradation of the cell cycle and the proliferation of malignant cells results in the loss of control mechanisms that ensure the normal function of tissues. The aim of the current review is to present the histopathological features of OSCC, including potentially malignant changes, the international classification of tumors, the tumor invasion front and tumor biomarkers (Ki-67, p53, homeobox genes and collagen type IV), as well as the tumor microenvironment and function of cancer-associated fibroblasts in the most common type of oral cancer that is encountered by dental surgeons. In OSCC, associations have been identified between the proliferation, basal lamina degradation and connective tissue modulation. Therefore, the comparison of these factors with the survival time of OSCC patients from the histopathological diagnosis is of interest.</p></abstract>
<kwd-group>
<kwd>mouth neoplasms</kwd>
<kwd>oral squamous cell carcinoma</kwd>
<kwd>oral cancer</kwd>
<kwd>p53</kwd>
<kwd>Ki-67</kwd>
<kwd>collagen type IV</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="other">
<title>1. Introduction</title>
<p>Head and neck cancer is one of the 10 most common types of cancer worldwide, afflicting &gt;500,000 individuals each year. Oral cancer is considered to be a preventable condition, due to the possibility of early detection and treatment (<xref rid="b1-ol-08-01-0007" ref-type="bibr">1</xref>). Oral squamous cell carcinoma (OSCC) represents 95&#x00025; of all forms of head and neck cancer, and during the past decade its incidence has increased by 50&#x00025; (<xref rid="b2-ol-08-01-0007" ref-type="bibr">2</xref>,<xref rid="b3-ol-08-01-0007" ref-type="bibr">3</xref>). Snuff and alcohol consumption are associated with 90&#x00025; of patients that exhibit oral cancer (<xref rid="b1-ol-08-01-0007" ref-type="bibr">1</xref>) and the two factors appear to have a synergistic effect (<xref rid="b4-ol-08-01-0007" ref-type="bibr">4</xref>).</p>
<p>The majority of OSCC are diagnosed at a late phase (<xref rid="b5-ol-08-01-0007" ref-type="bibr">5</xref>), in stages III or IV (<xref rid="b6-ol-08-01-0007" ref-type="bibr">6</xref>,<xref rid="b7-ol-08-01-0007" ref-type="bibr">7</xref>), which markedly decreases the chances of survival and leads to a significant deterioration in patient quality of life.</p>
<p>Despite the currently available therapeutic strategies, which include the excision of malignant tissue and combination of radiotherapy and chemotherapy, the five-year survival rate is only 53&#x00025; (<xref rid="b3-ol-08-01-0007" ref-type="bibr">3</xref>). In addition, a high percentage of patients have a poor response to therapy and high recurrence rates (<xref rid="b8-ol-08-01-0007" ref-type="bibr">8</xref>).</p>
<p>The purpose of the current review was to present the histological and molecular characteristics of the most common type of oral cancer encountered by dental surgeons.</p></sec>
<sec sec-type="other">
<title>2. Histology</title>
<p>In general, cancers, including OSCC, emerge from the accumulation of genetic changes and epigenetic anomalies in the signaling pathways that are associated with cancer, resulting in phenotypes that facilitate OSCC development. This process was summarized by Hanahan and Weinberg in &#x02018;Hallmarks of Cancer&#x02019; (<xref rid="b9-ol-08-01-0007" ref-type="bibr">9</xref>).</p>
<p>OSCC is a malignant neoplasm derived from the stratified squamous epithelium of the oral mucosa (<xref rid="b10-ol-08-01-0007" ref-type="bibr">10</xref>). Its pathogenesis is multifactorial, associated with cigarette smoke, alcohol (<xref rid="b11-ol-08-01-0007" ref-type="bibr">11</xref>) and snuff, as well as the papilloma virus, among others (<xref rid="b12-ol-08-01-0007" ref-type="bibr">12</xref>). The malignant neoplasm occurs at various sites, the most frequent being the lip, lateral edges of the tongue (<xref rid="f1-ol-08-01-0007" ref-type="fig">Fig. 1A</xref>) (<xref rid="b13-ol-08-01-0007" ref-type="bibr">13</xref>) and floor of the oral cavity. The incidence of OSCC increases with age, with the majority of OSCC occuring in patients &gt;40 years (<xref rid="b14-ol-08-01-0007" ref-type="bibr">14</xref>).</p>
<p>OSCC is characterized by histopathological and clinical manifestations. All carcinogenesis evolves from initial cell injury to the formation of a malignant neoplasm (<xref rid="b9-ol-08-01-0007" ref-type="bibr">9</xref>). Histologically, the lesion passes through various phases (preneoplastic damage) until the ultimate formation of a cancer. This carcinogenesis may be associated with precancerous lesions (such as leukoplakia, erythroplakia and mixed). However, it is necessary to consider that not all reactional lestions or potentially malignant lesions result in the subsequent development of malignant neoplasms (<xref rid="b15-ol-08-01-0007" ref-type="bibr">15</xref>).</p>
<sec>
<title>Potentially malignant changes</title>
<p>According to their histological appearance, lesions that present in the epithelium during the process of carcinogenesis may be classified according to their reactive epithelial changes (such as hyperkeratosis, hyperplasia and acanthosis) or preneoplastic changes (including mild, moderate and severe dysplasia; <xref rid="f1-ol-08-01-0007" ref-type="fig">Fig. 1B</xref>) (<xref rid="b16-ol-08-01-0007" ref-type="bibr">16</xref>) prior to the establishment of an invasive carcinoma (<xref rid="b12-ol-08-01-0007" ref-type="bibr">12</xref>,<xref rid="b14-ol-08-01-0007" ref-type="bibr">14</xref>,<xref rid="b17-ol-08-01-0007" ref-type="bibr">17</xref>). Oral cancer originates as an epithelial dysplasia and is characterized by the altered proliferation of dysplastic squamous cells on the surface of the epithelial layer, which subsequently degrades the subepithelial basement membrane (BM). Degradation of the BM results in local destruction and distant invasion via metastasis. Local invasion to the underlying tissue occurs via the islets and cords of epithelial cells (<xref rid="b18-ol-08-01-0007" ref-type="bibr">18</xref>).</p>
<p>The ability to metastasize is directly associated with the differential grade of tumor cells, similar to that of the neoplastic tissue architecture and normal epithelium (<xref rid="b14-ol-08-01-0007" ref-type="bibr">14</xref>).</p></sec>
<sec>
<title>International Classification of Tumors (World Health Organization) and the tumor invasion front (TIF)</title>
<p>Currently, two systems are used to histologically classify tumor lesions; the International Histological Classification of Tumors (<xref rid="f1-ol-08-01-0007" ref-type="fig">Fig. 1C&#x02013;E</xref>) and the pattern of the TIF (<xref rid="b19-ol-08-01-0007" ref-type="bibr">19</xref>). The initial classification of lesions is based on the degree of tumor differentiation (well-, moderately- and undifferentiated) (<xref rid="b20-ol-08-01-0007" ref-type="bibr">20</xref>), which is essential to evaluate the tumor&#x02019;s growth rate and ability to metastasize (<xref rid="b14-ol-08-01-0007" ref-type="bibr">14</xref>).</p>
<p>The TIF constitutes the area of the lesion with the greatest depth of invasion and progression into the surrounding tissues (<xref rid="b21-ol-08-01-0007" ref-type="bibr">21</xref>). In addition, the cells of the TIF have differing molecular characteristics when compared with the cells at the superficial areas of the tumor (<xref rid="b10-ol-08-01-0007" ref-type="bibr">10</xref>,<xref rid="b22-ol-08-01-0007" ref-type="bibr">22</xref>). The TIF is considered to be the most representative area of the tumor (<xref rid="b23-ol-08-01-0007" ref-type="bibr">23</xref>) and is identified by four characteristics; the degree of keratinization, nuclear polymorphism, lymphocytic infiltration and pattern of invasion (PI) (<xref rid="b23-ol-08-01-0007" ref-type="bibr">23</xref>,<xref rid="b24-ol-08-01-0007" ref-type="bibr">24</xref>). Of these, the PI is considered to be a good prognostic factor in OSCC (<xref rid="b1-ol-08-01-0007" ref-type="bibr">1</xref>). To evaluate the severity of the invasion, several morphological criteria exist, associated with certain PIs, according to the following three categories (<xref rid="f1-ol-08-01-0007" ref-type="fig">Fig. 1F&#x02013;I</xref>): i) Islet-infiltrating cells with wide fronts of invasion; ii) thin infiltrating cords; and iii) individual infiltrating cells (<xref rid="b1-ol-08-01-0007" ref-type="bibr">1</xref>).</p>
<p>In the clinical field, the majority of medical centers base their decisions upon the clinical and pathological information. The TNM stage (T, tumor size; N, regional lymph node compromise; and M, metastasis) (<xref rid="b25-ol-08-01-0007" ref-type="bibr">25</xref>) and the degree of tumor differentiation (<xref rid="b20-ol-08-01-0007" ref-type="bibr">20</xref>), combined with the patient&#x02019;s health status, are the predominant factors that determine the therapeutic strategy. To advance the knowledge of OSCC, numerous pathological and molecular clinical markers have been identified for the prediction of prognosis (<xref rid="b1-ol-08-01-0007" ref-type="bibr">1</xref>).</p></sec></sec>
<sec sec-type="other">
<title>3. Tumor biomarkers</title>
<p>Transformed neoplastic cells determine the biological behavior of the tumor. Aberrant cells, which posess common features, present a wide range of morphological and functional disorders.</p>
<p>Genetic and epigenetic alterations in OSCC lead to changes that include reduced expression or overexpression of proteins. The accumulation of these changes in oncogenes and tumor suppressor genes may lead to the formation of OSCC. The genes that are critically altered in OSCC include cyclin D1, p53, retinoblastoma, epidermal growth factor receptor, signal transducer and activator of transcription 3, and vascular endothelial growth factor receiver, as well as other molecules (<xref rid="b26-ol-08-01-0007" ref-type="bibr">26</xref>,<xref rid="b27-ol-08-01-0007" ref-type="bibr">27</xref>).</p>
<sec>
<title>Ki-67 and p53</title>
<p>Ki-67 and p53 are the most commonly used tumor markers for studying cell proliferation. The p53 protein is one of the transcription factors that is implicated in cell cycle control, apoptosis and preservation of genetic stability (<xref rid="b28-ol-08-01-0007" ref-type="bibr">28</xref>). In addition, the p53 gene is one of the most commonly mutated genes in OSCC with mutations detected in &gt;50&#x00025; of OSCC cases (<xref rid="b29-ol-08-01-0007" ref-type="bibr">29</xref>). The activation of p53 has been reported in a number of processes, such as DNA damage, hypoxia and oncogene activation. In addition, p53 protects against tumor formation by preventing the accumulation of cells with DNA damage, which subsequently induces a loss of function in the majority of malignant neoplasms (<xref rid="b30-ol-08-01-0007" ref-type="bibr">30</xref>). Although not completely understood, Ki-67 is considered to be an important protein in cell division, as it has been observed that the antigen is expressed primarily during the cell cycle stages of G1, S, G2 and M, with a marked emphasis on the M phase. However, Ki-67 expression is not observed during the G0 phase and has a low expression in the G1 and S phases (<xref rid="b31-ol-08-01-0007" ref-type="bibr">31</xref>). Furthermore, Ki-67 is considered to be one of the best predictors of survival (<xref rid="f1-ol-08-01-0007" ref-type="fig">Fig. 1J and K</xref>) (<xref rid="b16-ol-08-01-0007" ref-type="bibr">16</xref>) and recurrence (<xref rid="b5-ol-08-01-0007" ref-type="bibr">5</xref>).</p></sec>
<sec>
<title>Homeobox (HOX) genes</title>
<p>Recently, novel markers have been used to assess morphogenesis and cell differentiation. Previous studies have demonstrated that the aberrant expression of genes is associated with cancer embryogenesis, particularly the HOX genes that may induce embryological development, as well as contribute to the onset and progression of tumors (<xref rid="b32-ol-08-01-0007" ref-type="bibr">32</xref>,<xref rid="b33-ol-08-01-0007" ref-type="bibr">33</xref>). Furthermore, HOX gene overexpression has been associated with carcinogenesis, including head and neck neoplasms (<xref rid="b34-ol-08-01-0007" ref-type="bibr">34</xref>) and HOXB7, a member of the family of homeodomain transcription factors, is a critical regulator of development, controlling the proliferation and survival of progenitor cells. In OSCC, HOXB7 is overexpressed (<xref rid="f1-ol-08-01-0007" ref-type="fig">Fig. 1L and M</xref>) (<xref rid="b32-ol-08-01-0007" ref-type="bibr">32</xref>), which has been confirmed to be associated with a poor prognosis in OSCC and other types of cancer (<xref rid="b32-ol-08-01-0007" ref-type="bibr">32</xref>,<xref rid="b35-ol-08-01-0007" ref-type="bibr">35</xref>).</p></sec>
<sec>
<title>Collagen type IV (ColIV)</title>
<p>Infiltration is a key prerequisite for cancer metastasis, making it a significant factor in the prognosis of patients with OSCC (<xref rid="b36-ol-08-01-0007" ref-type="bibr">36</xref>). For the activation of the process, degradation of the BM must occur between the epithelium and lamina propria, which is located around the nest of cancer cells and blood vessels. The BM has been identified as a crucial structure in the regulation of tumor invasion. Its molecular assembly is a barrier for the invasion of the connective tissue, in particular of the epithelial cells, unless a molecular rupture occurs (<xref rid="b37-ol-08-01-0007" ref-type="bibr">37</xref>).</p>
<p>ColIV is the most important protein component of the BM and its integrity is altered by the degradation of the BM via matrix metalloproteinases (MMP) 2 and 9 that are present in OSCC (<xref rid="f1-ol-08-01-0007" ref-type="fig">Fig. 1N</xref>) (<xref rid="b38-ol-08-01-0007" ref-type="bibr">38</xref>) and the surrounding tissues (<xref rid="b36-ol-08-01-0007" ref-type="bibr">36</xref>). Furthermore, MMP 2 and 9 facilitate the development of lymph node metastases (<xref rid="b38-ol-08-01-0007" ref-type="bibr">38</xref>,<xref rid="b39-ol-08-01-0007" ref-type="bibr">39</xref>). Therefore, monitoring the changes in the expression of ColIV may have prognostic value in OSCC patients (<xref rid="b36-ol-08-01-0007" ref-type="bibr">36</xref>,<xref rid="b40-ol-08-01-0007" ref-type="bibr">40</xref>).</p></sec></sec>
<sec sec-type="other">
<title>4. Tumor microenvironment (TME)</title>
<p>For a number of years, cancer has been considered a cell-autonomous process in which consecutive mutations in the oncogenes and tumor suppressor genes lead to the infinite proliferation of neoplastic cells (<xref rid="b41-ol-08-01-0007" ref-type="bibr">41</xref>). Thus, cancer therapeutic strategies have been focused and limited on such mutations within the tumor cells (<xref rid="b4-ol-08-01-0007" ref-type="bibr">4</xref>). However, increasing evidence indicates that the genesis and progression of the tumor is determined by tumor cells as well as by a low TME (<xref rid="b42-ol-08-01-0007" ref-type="bibr">42</xref>).</p>
<p>Recent findings have indicated that for the effective control of cancer, the genesis and progression of the tumor must not only be considered to be cell-autonomous, but predominantly as a disease that involves complex heterotypic multicellular interactions within the newly formed tissue and the original cancerous tissue. Furthermore, the disease must be considered to be a a systemic, solid-tumor tissue disease rather than a single disease entity. Therefore, the concept of the TME has been proposed as an integral aspect and essential area of cancerous tissues. Recent evidence from a study concerning the TME has emerged, forcing the scientific community to review the basics of cancer biology (<xref rid="b43-ol-08-01-0007" ref-type="bibr">43</xref>).</p>
<p>The TME contains numerous types of cells, including fibroblasts, cancer-associated fibroblasts (CAFs), myofibroblasts, smooth muscle cells, endothelial cells and their precursors, pericytes, neutrophils, eosinophils, basophils, mast cells, T and B cells, natural killer cells, and antigen presenting cells, such as macrophages and dendritic cells (<xref rid="f2-ol-08-01-0007" ref-type="fig">Fig. 2</xref>).</p>
<sec>
<title>CAFs</title>
<p>Despite a marked recruitment of immune cells in the TME, immune cells do not represent the main population of tumor stromal cells; CAFs are the most abundant cells of the TME. CAFs are generally identified by the expression of &#x003B1;-smooth muscle actin, which is similar to the expression of myofibroblasts that occurrs at the site of wound healing and chronic inflammation, however, is absent in normal skin fibroblasts (<xref rid="b44-ol-08-01-0007" ref-type="bibr">44</xref>,<xref rid="b45-ol-08-01-0007" ref-type="bibr">45</xref>).</p>
<p>CAFs may be locally differentiated from normal fibroblasts or surrounding stromal stem cells that are derived from the mesenchymal cells of bone marrow, which is recruited by the tumor (<xref rid="b46-ol-08-01-0007" ref-type="bibr">46</xref>). The tumor stroma is rich in CAFs, which may be scattered or found in the tumor periphery. Certain evidence indicates that CAFs mechanically reshape the extracellular matrix, via the use of proteases, to facilitate the invasion of cancer cells (<xref rid="b4-ol-08-01-0007" ref-type="bibr">4</xref>). Previous studies have also demonstrated the existence of a molecular dialogue between CAFs and tumor cells, the latter of which secrete interleukin 1&#x003B1;, which stimulates the secretion of chemokine (CC motif) ligand 7 from the CAFs, resulting in tumor progression (<xref rid="b6-ol-08-01-0007" ref-type="bibr">6</xref>). The increased presence of CAFs observed in OSCC has been associated with a diffuse invasion pattern, preparing the environment for tumor invasion and metastasis (<xref rid="b47-ol-08-01-0007" ref-type="bibr">47</xref>), and is associated with a poor prognosis (<xref rid="b48-ol-08-01-0007" ref-type="bibr">48</xref>).</p></sec></sec>
<sec sec-type="other">
<title>5. Conclusion</title>
<p>In conclusion, an association between cell proliferation markers in the basal lamina and connective tissue has been identified in OSCC. In addition, hyperproliferative neoplastic cells may induce ColIV degradation and facilitate tumor invasion. Once installed in the connective tissue, the invading tumor cells may stimulate fibroblasts, which results in an increase in the presence of CAFs. This scenario may be associated with clinical and histopathological characteristics, in terms of a more aggressive stage of disease and a poor differentiation grade of tumor invasion, as well as the decreased survival time of patients with increased rates of cell proliferation, loss of BM integrity and CAF expression within the connective tissue.</p>
<p>Therefore, the comparison of these factors with the survival time of OSCC patients, from the time of histopathological diagnosis, is of interest. The results of the present review may be useful to clarify the tumor-stromal interaction, and its significance regarding the clinical and histological characteristics of OSCC, in order to expand the quantity of specific prognostic factors available as alternatives to the classic TNM.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors would like to thank the Investigations Directorate (DI) and the Master Program of Biomedical Sciences, University of Talca (Talca, Chile) for its cooperation.</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-ol-08-01-0007"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dissanayaka</surname><given-names>WL</given-names></name><name><surname>Pitiyage</surname><given-names>G</given-names></name><name><surname>Kumarasiri</surname><given-names>PV</given-names></name><name><surname>Liyanage</surname><given-names>RL</given-names></name><name><surname>Dias</surname><given-names>KD</given-names></name><name><surname>Tilakaratne</surname><given-names>WM</given-names></name></person-group><article-title>Clinical and histopathologic parameters in survival of oral squamous cell carcinoma</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol</source><volume>113</volume><fpage>518</fpage><lpage>525</lpage><year>2012</year></element-citation></ref>
<ref id="b2-ol-08-01-0007"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Sankila</surname><given-names>R</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name></person-group><article-title>Estimates of cancer incidence and mortality in Europe in 1995</article-title><source>Eur J Cancer</source><volume>38</volume><fpage>99</fpage><lpage>166</lpage><year>2002</year></element-citation></ref>
<ref id="b3-ol-08-01-0007"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>D</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name></person-group><article-title>Global cancer statistics, 2002</article-title><source>CA Cancer J Clin</source><volume>55</volume><fpage>74</fpage><lpage>108</lpage><year>2005</year></element-citation></ref>
<ref id="b4-ol-08-01-0007"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koontongkaew</surname><given-names>S</given-names></name></person-group><article-title>The tumor microenvironment contribution to development, growth, invasion and metastasis of head and necksquamous cell carcinomas</article-title><source>J Cancer</source><volume>4</volume><fpage>66</fpage><lpage>83</lpage><year>2013</year></element-citation></ref>
<ref id="b5-ol-08-01-0007"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wangsa</surname><given-names>D</given-names></name><name><surname>Ryott</surname><given-names>M</given-names></name><name><surname>Avall-Lundqvist</surname><given-names>E</given-names></name><etal/></person-group><article-title>Ki-67 expression predicts locoregional recurrence in stage I oral tongue carcinoma</article-title><source>Br J Cancer</source><volume>99</volume><fpage>1121</fpage><lpage>1128</lpage><year>2008</year></element-citation></ref>
<ref id="b6-ol-08-01-0007"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>DW</given-names></name><name><surname>Che</surname><given-names>ZM</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>KY</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name></person-group><article-title>Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7</article-title><source>Int J Cancer</source><volume>127</volume><fpage>332</fpage><lpage>344</lpage><year>2010</year></element-citation></ref>
<ref id="b7-ol-08-01-0007"><label>7</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Centelles</surname><given-names>PV</given-names></name><name><surname>Seoane-Romero</surname><given-names>JM</given-names></name><name><surname>G&#x000F3;mez</surname><given-names>I</given-names></name><name><surname>Diz-Dios</surname><given-names>P</given-names></name><name><surname>de Melo</surname><given-names>NS</given-names></name><name><surname>Seoane</surname><given-names>J</given-names></name></person-group><article-title>Timing of oral cancer diagnosis: Implications for prognosis and survival</article-title><source>Oral Cancer</source><person-group person-group-type="editor"><name><surname>Ogbureke</surname><given-names>KUE</given-names></name></person-group><publisher-name>InTech</publisher-name><fpage>173</fpage><lpage>188</lpage><year>2012</year></element-citation></ref>
<ref id="b8-ol-08-01-0007"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettendorf</surname><given-names>O</given-names></name><name><surname>Piffk&#x000F2;</surname><given-names>J</given-names></name><name><surname>B&#x000E0;nkfalvi</surname><given-names>A</given-names></name></person-group><article-title>Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy?</article-title><source>Oral Oncol</source><volume>40</volume><fpage>110</fpage><lpage>119</lpage><year>2004</year></element-citation></ref>
<ref id="b9-ol-08-01-0007"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>The hallmarks of cancer</article-title><source>Cell</source><volume>100</volume><fpage>57</fpage><lpage>70</lpage><year>2000</year></element-citation></ref>
<ref id="b10-ol-08-01-0007"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumuluri</surname><given-names>V</given-names></name><name><surname>Thomas</surname><given-names>GA</given-names></name><name><surname>Fraser</surname><given-names>IS</given-names></name></person-group><article-title>Analysis of the Ki-67 antigen at the invasive tumour front of human oral squamous cell carcinoma</article-title><source>J Oral Pathol Med</source><volume>31</volume><fpage>598</fpage><lpage>604</lpage><year>2002</year></element-citation></ref>
<ref id="b11-ol-08-01-0007"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkey</surname><given-names>JF</given-names></name><name><surname>Buchberger</surname><given-names>G</given-names></name><name><surname>Saucier</surname><given-names>K</given-names></name><etal/></person-group><article-title>Cyclin D1 overexpression increases susceptibility to 4-nitroquinoline-1 -oxide-induced dysplasia and neoplasia in murine squamous oral epithelium</article-title><source>Mol Carcinog</source><volume>48</volume><fpage>853</fpage><lpage>861</lpage><year>2009</year></element-citation></ref>
<ref id="b12-ol-08-01-0007"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Neville</surname><given-names>B</given-names></name><name><surname>Damm</surname><given-names>D</given-names></name><name><surname>Allen</surname><given-names>C</given-names></name><name><surname>Bouquot</surname><given-names>J</given-names></name></person-group><source>Oral and Maxillofacial Pathology</source><edition>3rd edition</edition><publisher-name>Saunders Elsevier</publisher-name><publisher-loc>Philadelphia, PA</publisher-loc><fpage>356</fpage><lpage>367</lpage><year>2009</year></element-citation></ref>
<ref id="b13-ol-08-01-0007"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jerjes</surname><given-names>W</given-names></name><name><surname>Upile</surname><given-names>T</given-names></name><name><surname>Petrie</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1&#x02013;T2 oral squamous cell carcinoma patients</article-title><source>Head Neck Oncol</source><volume>2</volume><fpage>9</fpage><year>2010</year></element-citation></ref>
<ref id="b14-ol-08-01-0007"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sapp</surname><given-names>JP</given-names></name><name><surname>Eversole</surname><given-names>LR</given-names></name><name><surname>Wysocki</surname><given-names>GP</given-names></name></person-group><source>Contemporary Oral and Maxillofacial Pathology Chapter 6: Epithelial Disorders</source><edition>2nd edition</edition><publisher-name>Mosby Year Book Inc</publisher-name><publisher-loc>Maryland Heights, MO</publisher-loc><fpage>184</fpage><lpage>193</lpage><year>2004</year></element-citation></ref>
<ref id="b15-ol-08-01-0007"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neville</surname><given-names>BW</given-names></name><name><surname>Day</surname><given-names>TA</given-names></name></person-group><article-title>Oral cancer and precancerous lesions</article-title><source>CA Cancer J Clin</source><volume>52</volume><fpage>195</fpage><lpage>215</lpage><year>2002</year></element-citation></ref>
<ref id="b16-ol-08-01-0007"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><etal/></person-group><article-title>RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67</article-title><source>Eur J Cancer</source><volume>45</volume><fpage>490</fpage><lpage>496</lpage><year>2009</year></element-citation></ref>
<ref id="b17-ol-08-01-0007"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>MCA</given-names></name></person-group><article-title>4NQO carcinogenesis: A model of oral squamous cell carcinoma</article-title><source>Int J Morphol</source><volume>30</volume><fpage>309</fpage><lpage>314</lpage><year>2012</year></element-citation></ref>
<ref id="b18-ol-08-01-0007"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuentes</surname><given-names>B</given-names></name><name><surname>Duaso</surname><given-names>J</given-names></name><name><surname>Droguett</surname><given-names>D</given-names></name><etal/></person-group><article-title>Progressive extracellular matrix disorganization in chemically induced murine oral squamous cell carcinoma</article-title><source>ISRN Pathology</source><year>2012</year></element-citation></ref>
<ref id="b19-ol-08-01-0007"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>CA</given-names></name><name><surname>Droguett</surname><given-names>DA</given-names></name><name><surname>Kemmerling</surname><given-names>U</given-names></name><name><surname>Venegas</surname><given-names>BA</given-names></name></person-group><article-title>Chronic restraint stress in oral squamous cell carcinoma</article-title><source>J Dent Res</source><volume>90</volume><fpage>799</fpage><lpage>803</lpage><year>2011</year></element-citation></ref>
<ref id="b20-ol-08-01-0007"><label>20</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pindborg</surname><given-names>JJ</given-names></name><name><surname>Reichart</surname><given-names>PA</given-names></name><name><surname>Smith</surname><given-names>CJ</given-names></name><name><surname>Van der Waal</surname><given-names>I</given-names></name></person-group><source>WHO International Histological Classification of Tumours Histological typing of cancer and precancer of the oral mucosa</source><publisher-name>Springer-Verlag</publisher-name><publisher-loc>New York</publisher-loc><year>1997</year></element-citation></ref>
<ref id="b21-ol-08-01-0007"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>M</given-names></name><etal/></person-group><article-title>The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: immunohistochemical and RT-PCR analysis with clinicopathological correlation</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source><volume>107</volume><fpage>547</fpage><lpage>554</lpage><year>2009</year></element-citation></ref>
<ref id="b22-ol-08-01-0007"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000E0;nkfalvi</surname><given-names>A</given-names></name><name><surname>Piffk&#x000F2;</surname><given-names>J</given-names></name></person-group><article-title>Prognostic and predictive factors in oral cancer: the role of the invasive tumour front</article-title><source>J Oral Pathol Med</source><volume>29</volume><fpage>291</fpage><lpage>298</lpage><year>2000</year></element-citation></ref>
<ref id="b23-ol-08-01-0007"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurokawa</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>The high prognostic value of the histologic grade at the deep invasive front of tongue squamous cell carcinoma</article-title><source>J Oral Pathol Med</source><volume>34</volume><fpage>329</fpage><lpage>333</lpage><year>2005</year></element-citation></ref>
<ref id="b24-ol-08-01-0007"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryne</surname><given-names>M</given-names></name><name><surname>Koppang</surname><given-names>HS</given-names></name><name><surname>Lilleng</surname><given-names>R</given-names></name><name><surname>Kjaerheim</surname><given-names>A</given-names></name></person-group><article-title>Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value</article-title><source>J Pathol</source><volume>166</volume><fpage>375</fpage><lpage>381</lpage><year>2005</year></element-citation></ref>
<ref id="b25-ol-08-01-0007"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>L</given-names></name><name><surname>Ribeiro-Silva</surname><given-names>A</given-names></name><name><surname>Costa</surname><given-names>J</given-names></name><name><surname>Sim&#x000F5;es</surname><given-names>A</given-names></name><name><surname>Matteo</surname><given-names>M</given-names></name><name><surname>Zucoloto</surname><given-names>S</given-names></name></person-group><article-title>Prognostic factors and survival analysis in a sample of oral squamous cell carcinoma patients</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source><volume>106</volume><fpage>685</fpage><lpage>695</lpage><year>2008</year></element-citation></ref>
<ref id="b26-ol-08-01-0007"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leemans</surname><given-names>CR</given-names></name><name><surname>Braakhuis</surname><given-names>BJ</given-names></name><name><surname>Brakenhoff</surname><given-names>RH</given-names></name></person-group><article-title>The molecular biology of head and neck cancer</article-title><source>Nat Rev Cancer</source><volume>11</volume><fpage>9</fpage><lpage>22</lpage><year>2010</year></element-citation></ref>
<ref id="b27-ol-08-01-0007"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name></person-group><article-title>Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy</article-title><source>J Dent Res</source><volume>87</volume><fpage>14</fpage><lpage>32</lpage><year>2008</year></element-citation></ref>
<ref id="b28-ol-08-01-0007"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massano</surname><given-names>J</given-names></name><name><surname>Regateiro</surname><given-names>F</given-names></name><name><surname>Janu&#x000E1;rio</surname><given-names>G</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name></person-group><article-title>Oral squamous cell carcinoma: review of prognostic and predictive factors</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source><volume>102</volume><fpage>67</fpage><lpage>76</lpage><year>2006</year></element-citation></ref>
<ref id="b29-ol-08-01-0007"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Houten</surname><given-names>VM</given-names></name><name><surname>Tabor</surname><given-names>MP</given-names></name><name><surname>van den Brekel</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Mutated p53 as a molecular marker for the diagnosis of head and neck cancer</article-title><source>J Pathol</source><volume>198</volume><fpage>476</fpage><lpage>486</lpage><year>2002</year></element-citation></ref>
<ref id="b30-ol-08-01-0007"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maddocks</surname><given-names>OD</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name></person-group><article-title>Metabolic regulation by p53</article-title><source>J Mol Med (Berl)</source><volume>89</volume><fpage>237</fpage><lpage>245</lpage><year>2011</year></element-citation></ref>
<ref id="b31-ol-08-01-0007"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yerushalmi</surname><given-names>R</given-names></name><name><surname>Woods</surname><given-names>R</given-names></name><name><surname>Ravdin</surname><given-names>PM</given-names></name><name><surname>Hayes</surname><given-names>M</given-names></name><name><surname>Gelmon</surname><given-names>KA</given-names></name></person-group><article-title>Ki-67 in breast cancer: prognostic and predictive potential</article-title><source>Lancet Oncol</source><volume>11</volume><fpage>174</fpage><year>2010</year></element-citation></ref>
<ref id="b32-ol-08-01-0007"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bitu</surname><given-names>CC</given-names></name><name><surname>Carrera</surname><given-names>M</given-names></name><name><surname>Lopes</surname><given-names>MA</given-names></name><name><surname>Kowalski</surname><given-names>LP</given-names></name><name><surname>Soares</surname><given-names>FA</given-names></name><name><surname>Coletta</surname><given-names>RD</given-names></name></person-group><article-title>HOXB7 expression is a prognostic factor for oral squamous cell carcinoma</article-title><source>Histopathology</source><volume>60</volume><fpage>662</fpage><lpage>665</lpage><year>2012</year></element-citation></ref>
<ref id="b33-ol-08-01-0007"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Sukumar</surname><given-names>S</given-names></name></person-group><article-title>The Hox genes and their roles in oncogenesis</article-title><source>Nat Rev Cancer</source><volume>10</volume><fpage>361</fpage><lpage>371</lpage><year>2010</year></element-citation></ref>
<ref id="b34-ol-08-01-0007"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tucci</surname><given-names>R</given-names></name><name><surname>Campos</surname><given-names>MS</given-names></name><name><surname>Matizonkas-Antonio</surname><given-names>LF</given-names></name><name><surname>Durazzo</surname><given-names>M</given-names></name><name><surname>dos Pinto Junior</surname><given-names>DS</given-names></name><name><surname>Nunes</surname><given-names>FD</given-names></name></person-group><article-title>HOXB5 expression in oral squamous cell carcinoma</article-title><source>J Appl Oral Sci</source><volume>19</volume><fpage>125</fpage><lpage>129</lpage><year>2011</year></element-citation></ref>
<ref id="b35-ol-08-01-0007"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>WT</given-names></name><name><surname>Jiang</surname><given-names>D</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><etal/></person-group><article-title>HOXB7 as a prognostic factor and mediator of colorectal cancer progression</article-title><source>Clin Cancer Res</source><volume>17</volume><fpage>3569</fpage><lpage>3578</lpage><year>2011</year></element-citation></ref>
<ref id="b36-ol-08-01-0007"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>HX</given-names></name><name><surname>Li</surname><given-names>HX</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>ZX</given-names></name><name><surname>Zheng</surname><given-names>JH</given-names></name></person-group><article-title>Changes in the expression of MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell carcinoma: relationships and prognostic implications</article-title><source>J Exp Clin Cancer Res</source><volume>31</volume><fpage>90</fpage><year>2012</year></element-citation></ref>
<ref id="b37-ol-08-01-0007"><label>37</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Abbas</surname><given-names>AK</given-names></name><name><surname>Aster</surname><given-names>JC</given-names></name></person-group><source>Robbins Basic Pathology Chapter 7: Neoplasia</source><edition>8th ed</edition><publisher-name>Saunders</publisher-name><publisher-loc>Philadelphia, PA</publisher-loc><fpage>298</fpage><lpage>299</lpage><year>2012</year></element-citation></ref>
<ref id="b38-ol-08-01-0007"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamamura</surname><given-names>R</given-names></name><name><surname>Nagatsuka</surname><given-names>H</given-names></name><name><surname>Siar</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Comparative analysis of basal lamina type IV collagen alpha chains, matrix metalloproteinases-2 and &#x02212;9 expressions in oral dysplasia and invasive carcinoma</article-title><source>Acta Histochem</source><volume>115</volume><fpage>113</fpage><lpage>119</lpage><year>2013</year></element-citation></ref>
<ref id="b39-ol-08-01-0007"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vicente</surname><given-names>JC</given-names></name><name><surname>Fresno</surname><given-names>MF</given-names></name><name><surname>Villalain</surname><given-names>L</given-names></name><name><surname>Vega</surname><given-names>JA</given-names></name><name><surname>Hern&#x000E1;ndez Vallejo</surname><given-names>G</given-names></name></person-group><article-title>Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma</article-title><source>Oral Oncol</source><volume>41</volume><fpage>283</fpage><lpage>293</lpage><year>2005</year></element-citation></ref>
<ref id="b40-ol-08-01-0007"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>Y</given-names></name><name><surname>Iyama</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><etal/></person-group><article-title>The Expression of type IV collagen &#x003B1;6 chain is related to the prognosis in patients with esophageal squamous cell carcinoma</article-title><source>Ann Surg Oncol</source><volume>15</volume><fpage>555</fpage><lpage>565</lpage><year>2008</year></element-citation></ref>
<ref id="b41-ol-08-01-0007"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenny</surname><given-names>PA</given-names></name><name><surname>Lee</surname><given-names>GY</given-names></name><name><surname>Bissell</surname><given-names>MJ</given-names></name></person-group><article-title>Targeting the tumor microenvironment</article-title><source>Front Biosci</source><volume>12</volume><fpage>3468</fpage><lpage>3474</lpage><year>2007</year></element-citation></ref>
<ref id="b42-ol-08-01-0007"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Tumor stroma as targets for cancer therapy</article-title><source>Pharmacol Ther</source><volume>137</volume><fpage>200</fpage><lpage>215</lpage><year>2013</year></element-citation></ref>
<ref id="b43-ol-08-01-0007"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liotta</surname><given-names>LA</given-names></name><name><surname>Kohn</surname><given-names>EC</given-names></name></person-group><article-title>The microenvironment of the tumour-host interface</article-title><source>Nature</source><volume>411</volume><fpage>375</fpage><lpage>379</lpage><year>2001</year></element-citation></ref>
<ref id="b44-ol-08-01-0007"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimoda</surname><given-names>M</given-names></name><name><surname>Mellody</surname><given-names>KT</given-names></name><name><surname>Orimo</surname><given-names>A</given-names></name></person-group><article-title>Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression</article-title><source>Semin Cell Dev Biol</source><volume>21</volume><fpage>19</fpage><lpage>25</lpage><year>2010</year></element-citation></ref>
<ref id="b45-ol-08-01-0007"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000E4;s&#x000E4;nen</surname><given-names>K</given-names></name><name><surname>Vaheri</surname><given-names>A</given-names></name></person-group><article-title>Activation of fibroblasts in cancer stroma</article-title><source>Exp Cell Res</source><volume>316</volume><fpage>2713</fpage><lpage>2722</lpage><year>2010</year></element-citation></ref>
<ref id="b46-ol-08-01-0007"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xouri</surname><given-names>G</given-names></name><name><surname>Christian</surname><given-names>S</given-names></name></person-group><article-title>Origin and function of tumor stroma fibroblasts</article-title><source>Semin Cell Dev Biol</source><volume>21</volume><fpage>40</fpage><lpage>46</lpage><year>2010</year></element-citation></ref>
<ref id="b47-ol-08-01-0007"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de-Assis</surname><given-names>EM</given-names></name><name><surname>Pimenta</surname><given-names>LG</given-names></name><name><surname>Costa-e-Silva</surname><given-names>E</given-names></name><name><surname>Souza</surname><given-names>PE</given-names></name><name><surname>Horta</surname><given-names>MC</given-names></name></person-group><article-title>Stromal myofibroblasts in oral leukoplakia and oral squamous cell carcinoma</article-title><source>Med Oral Patol Oral Cir Bucal</source><volume>17</volume><fpage>e733</fpage><lpage>e738</lpage><year>2012</year></element-citation></ref>
<ref id="b48-ol-08-01-0007"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thode</surname><given-names>C</given-names></name><name><surname>J&#x000F8;rgensen</surname><given-names>TG</given-names></name><name><surname>Dabelsteen</surname><given-names>E</given-names></name><name><surname>Mackenzie</surname><given-names>I</given-names></name><name><surname>Dabelsteen</surname><given-names>S</given-names></name></person-group><article-title>Significance of myofibroblasts in oral squamous cell carcinoma</article-title><source>J Oral Pathol Med</source><volume>40</volume><fpage>201</fpage><lpage>207</lpage><year>2011</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-ol-08-01-0007" position="float">
<label>Figure 1</label>
<caption>
<p>(A) Oral squamous cell carcinoma (OSCC) of the lateral edge of the tongue (<xref rid="b13-ol-08-01-0007" ref-type="bibr">13</xref>). (B) Severe dysplasia of the surface epithelium associated with chronic inflammatory infiltration at the stromal-epithelial interface of the dysplastic epithelium (stain, H&amp;E; magnification, &#x000D7;50) (<xref rid="b13-ol-08-01-0007" ref-type="bibr">13</xref>). Histological grades of tumor differentiation of OSCC: (C) Well-differentiated, hyperkeratosis and inflammation associated with the stromal-epithelial interface; (D) moderately differentiated; and (E) undifferentiated infiltrating and dispersed cells with no clear demarcation between the front and surrounding tissue invasion (stain, H&amp;E; magnification, &#x000D7;25) (<xref rid="b13-ol-08-01-0007" ref-type="bibr">13</xref>). Different patterns of invasion at the tumor invasion front according to the cell morphology: (F) Wide fronts of invasion (score 1); (G) islet cell widths (score 1); (H) thin infiltrating cords (score 2); and (I) individual cells invading the interface (score 3) (<xref rid="b1-ol-08-01-0007" ref-type="bibr">1</xref>). OSCC patients (J) with recurrence and (K) without recurrence. Antibody staining for Ki-67 with a high degree of nuclear staining (magnification, &#x000D7;400) (<xref rid="b16-ol-08-01-0007" ref-type="bibr">16</xref>). Representative samples of homeobox protein, HOXB7 immunohistochemical expression in OSCC with (L) high and (M) low expression (<xref rid="b32-ol-08-01-0007" ref-type="bibr">32</xref>). (N) Immunohistochemical expression of type IV collagen &#x003B1;2 chain in undifferentiated OSCC (<xref rid="b38-ol-08-01-0007" ref-type="bibr">38</xref>).</p></caption>
<graphic xlink:href="OL-08-01-0007-g00.gif"/></fig>
<fig id="f2-ol-08-01-0007" position="float">
<label>Figure 2</label>
<caption>
<p>In the tumoral microenvironment (TME), different stromal cells, as well as tumor cells were observed, including vascular and lymphatic endothelial cells, and pericyte support fibroblast innate and adaptive immune cells. Furthermore, the TME contained no cellular components, including the extracellular matrix, growth factors, proteases, protease inhibitors or other signaling molecules that are significant in the reactions of the stroma in the TME (<xref rid="b4-ol-08-01-0007" ref-type="bibr">4</xref>).</p></caption>
<graphic xlink:href="OL-08-01-0007-g01.gif"/></fig></floats-group></article>
